1. Value in Health Regional Issues
Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection 
Philip McEwan, PhD, Thomas Ward, MSc, Chien-Jen Chen, PhD, Mei-Hsuan Lee, PhD, Hwai-I Yang, PhD, Ray Kim, MD, Gilbert L’Italien, PhD, Yong Yuan, PhD 
Value in Health Regional Issues 
Volume 3, Pages 5-11 (May 2014)
DOI: /j.vhri
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Incident cases of confirmed HCC in Taiwan with estimated HCV-related HCC. HCV, hepatitis C virus.
Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Flow diagram of the MONARCH model. Annual transition probabilities control progression through disease states. HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Estimated cumulative number of chronic hepatitis C infections with bootstrapped 95% confidence intervals. HCV, hepatitis C virus.
Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cumulative estimated prevalence of chronic HCV by fibrosis stage. As of 2012, it is estimated that 23.0%, 19.0%, 14.6%, 22.3%, and 21.1% of the 555,313 patients with chronic HCV are in fibrosis sages F1, F2, F3, and F4, respectively.
Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Estimated prevalence of chronic HCV with varying ‘minimum incidence caps.’ HCV, hepatitis C virus.
Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

7. Fig. 6
(A) Estimated prevalence of hepatocellular carcinoma and chronic HCV per year. (B) Estimated incidence of liver transplants and liver-related deaths per year. HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions